Alvocidib (Flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis

Surgical Oncology

Volumn 15, Issue 2, 2006, Pages 107-113

  Sato, Shinsuke ^a   Kajiyama, Yoshiaki ^a   Sugano, Masahiko ^a   Iwanuma, Yoshimi ^a   Sonoue, Hiroshi ^a   Matsumoto, Toshiharu ^a   Tsurumaru, Masahiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alvocidib; Cyclin D1; Esophageal cancer; VEGF; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; EOSIN; FLAVOPIRIDOL; HEMATOXYLIN; PROTEIN BCL 2; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN D1; ESOPHAGEAL NEOPLASMS; FEMALE; FLAVONOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, SCID; NECROSIS; NEOPLASM TRANSPLANTATION; PIPERIDINES; RETINOBLASTOMA PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33751119324     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2006.10.001     Document Type: Article

References (41)

1. Enzinger P.C., and Mayer R.J. Esophageal cancer. New England Journal of Medicine 349 (2004) 2241-2252
2. Van Meerten E., and Van der Gaast A. Systemic treatment for oesophageal cancer. European Journal of Cancer 41 (2005) 664-672
3. Bosset J.F., Gignoux M., Triboulet J.P., Tiret E., Mantion G., Elias D., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. New England Journal of Medicine 337 (1997) 161-167
4. Kelsen D.P., Ginsberg R., Pajak T.F., Sheahan D.G., Gunderson L., Mortimer J., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. New England Journal of Medicine 339 (1998) 1979-1984
5. Swanton C. Cell-cycle targeted therapies. Lancet Oncology 5 (2004) 27-36
6. de Azevedo Jr. W.F., Canduri F., and da Silveira N.J. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochemical and Biophysical Research Communications 293 (2002) 566-571
7. Chao S.H., and Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. Journal of Biological Chemistry 276 (2001) 31793-31799
8. Senderowicz A.M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22 (2003) 6609-6620
9. Zhai S., Senderowicz A.M., Sausville E.A., and Figg W.D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Annals of Pharmacotherapy 36 (2002) 905-911
10. Shapiro G.I., Supko J.G., Patterson A., Lynch C., Lucca J., Zacarola P.F., et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clinical Cancer Research 7 (2001) 1590-1599
11. Van Veldhuizen P.J., Faulkner J.R., Lara Jr. P.N., Gumerlock P.H., Goodwin J.W., Dakhil S.R., et al. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemotherapy and Pharmacology 56 (2005) 39-45
12. Schrump D.S., Matthews W., Chen G.A., Mixon A., and Altorki N.K. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clinical Cancer Research 4 (1998) 2885-2890
13. Sato S., Kajiyama Y., Sugano M., Iwanuma Y., and Tsurumaru M. Flavopiridol as a radiosensitizer for esophageal cancer cell lines. Diseases of the Esophagus 17 (2004) 338-344
14. Lechpammer M., Xu X., Ellis F.H., Bhattacharaya N., Shapiro G.I., and Loda M. Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice. Oncogene 24 (2005) 1683-1688
15. Nishimura T., Hashimoto Y., Katayama M., Mori S., and Kuroki T. Molecular and cellular features of esophageal cancer cells. Journal of Cancer Research and Clinical Oncology 119 (1993) 441-449
16. Czech J., Hoffman D., Naik R., and Sedlacek H.-H. Antitumoral activity of flavone L86-8275. International Journal of Oncology 6 (1995) 31-36
17. Patel V., Senderowicz A.M., Pinto Jr. D., Igishi T., Raffeld M., Quintanilla-Martinez L., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Journal of Clinical Investigation 102 (1998) 1674-1681
18. Drees M., Dengler W.A., Roth T., Labonte H., Mayo J., Malspeis L., et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clinical Cancer Research 3 (1997) 273-279
19. Arguello F., Alexander M., Sterry J.A., Tudor G., Smith E.M., Kalavar N.T., et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent anti-tumor activity In vivo against human leukemia and lymphoma xenografts. Blood 91 (1998) 2482-2490
20. Bible K.C., and Kaufmann S.H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Research 56 (1996) 4856-4861
21. Ma Y., Cress W.D., and Haura E.B. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Molecular Cancer Therapy 2 (2003) 73-81
22. Konig A., Schwartz G.K., Mohammad R.M., Al-Katib A., and Gabrilove J.L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90 (1997) 4307-4312
23. Li Y., Bhuiyan M., Alhasan S., Senderowicz A.M., and Sarkar F.H. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clinical Cancer Research 6 (2000) 223-229
24. Alonso M., Tamasdan C., Miller D.C., and Newcomb E.W. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Molecular Cancer Therapy 2 (2003) 139-150
25. Parker B.W., Kaur G., Nieves-Neira W., Taimi M., Kohlhagen G., Shimizu T., et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91 (1998) 458-465
26. Byrd J.C., Shinn C., Waselenko J.K., Fuchs E.J., Lehman T.A., Nguyen P.L., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92 (1998) 3804-3816
27. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., and Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Research 56 (1996) 2973-2978
28. Tomida A., Suzuki H., Kim H.D., and Tsuruo T. Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene 13 (1996) 2699-2705
29. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
30. Maxwell P.H., and Ratcliffe P.J. Oxygen sensors and angiogenesis. Seminars in Cell and Developmental Biology 13 (2002) 29-37
31. Kleespies A., Guba M., Jauch K.W., and Bruns C.J. Vascular endothelial growth factor in esophageal cancer. Journal of Surgical Oncology 87 (2004) 95-104
32. Byeon J.S., Jung H.Y., Lee Y.J., Lee D., Lee G.H., Myung S.J., et al. Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma. Journal of Gastroenterology and Hepatology 19 (2004) 648-654
33. Melillo G., Sausville E.A., Cloud K., Lahusen T., Varesio L., and Senderowicz A.M. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Research 59 (1999) 5433-5437
34. Rapella A., Negrioli A., Melillo G., Pastorino S., Varesio L., and Bosco M.C. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. International Journal of Cancer 99 (2002) 658-664
35. Sedlacek H.H. Mechanisms of action of flavopiridol. Critical Reviews in Oncology and Hematology 38 (2001) 139-170
36. Ikeguchi M., Sakatani T., Ueta T., and Kaibara N. Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology 127 (2001) 531-536
37. Guner D., Sturm I., Hemmati P., Hermann S., Hauptmann S., Wurm R., et al. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. International Journal of Cancer 103 (2003) 445-454
38. Nakamura T., Ide H., Eguchi R., Hayashi K., and Takasaki K. Concomitant analysis of p16/INK4, cyclin D1, and retinoblastoma protein expression in esophageal squamous cell carcinoma. Hepatogastroenterology 50 (2003) 1321-1326
39. Arber N., Gammon M.D., Hibshoosh H., Britton J.A., Zhang Y., Schonberg J.B., et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Human Pathology 30 (1999) 1087-1092
40. Shiozaki H., Doki Y., Yamana H., and Isono K. A multi-institutional study of immunohistochemical investigation for the roles of cyclin D1 and E-cadherin in superficial squamous cell carcinoma of the esophagus. Journal of Surgical Oncology 79 (2002) 166-173
41. Shamma A., Doki Y., Shiozaki H., Tsujinaka T., Yamamoto M., Inoue M., et al. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. International Journal of Oncology 16 (2000) 261-266